- $2.46m
- $0.79m
- $0.13m
Brief: Organovo Holdings Appoints Norman Staskey As President And CFO
Organovo Holdings Inc reports results for the quarter ended September 30 - Earnings Summary
Organovo Holdings Inc reports results for the quarter ended in June - Earnings Summary
Organovo Holdings up after fatty liver drug meets main goal in mid-stage study
Brief: Organovo Announces Positive Phase 2 Results for FXR314
Organovo's fatty liver disease drug meets main goal in mid-stage study (updated)
Organovo's fatty liver disease drug meets main goal in mid-stage study
Brief: Organovo Holdings Files For Offering Shares Of Common Stock, Size Not Disclosed
Organovo Holdings Inc reports results for the quarter ended in December - Earnings Summary
Brief: Organovo Holdings Entered Into A Sales Agreement Relating To Shares Of Common Stock
Brief: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
Brief: Organovo Highlights FXR314 Combination Therapy Potential and Plan
Brief: Organovo Advances Clinical Timelines For Fxr314 And Provides Updates On Nash Phase 2 Data
Brief: Organovo Holdings Announced A Plan To Reduce Company's Workforce, Effective August 25
Brief: Organovo Announces Fxr Program
Brief: Organovo Announces Target Validation Ahead Of Schedule, Accelerating Timeline For First Crohn’S Disease Drug Candidates
Brief: Organovo Achieves 3D Tissue Model For Crohn's Disease
Brief: Organovo And BICO Reach Licensing Agreement On Bioprinting Patents
Brief: Organovo Guides On Patent Portfolio And Successful Ipr Defense Of Two Patents